# A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

> **NCT01021059** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Melanoma
- Carcinoma, Renal Cell

## Interventions

- **BIOLOGICAL:** rh IL-15

## Key facts

- **NCT ID:** NCT01021059
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-10
- **Primary completion:** 2013-05-31
- **Final completion:** 2016-10-25
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01021059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01021059, "A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01021059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*